Nano COVID-19 Vaccines: the firsts RNA lipid nanoparticle vaccines being approved from history - Review
DOI:
https://doi.org/10.33448/rsd-v9i12.11123Keywords:
COVID-19; Coronavirus; Vaccine; Nanomedicine; Nanotechnology.Abstract
A new coronavirus, identified in Wuhan, China, has spread globally, infecting millions of people and causing significant morbidity and mortality. The pandemic state, declared by the World Health Organization on March 11, 2020, transformed the world and made people adapt to social distance to control the spread of the virus. The race against time in search of therapeutic solutions has become essential, and nanotechnology may be able to make vaccines available in record time to stimulate the immunization of individuals. Since the beginning of 2020, scientists and companies are rapidly advancing to make vaccine candidates available at a different rate compared to other pandemics that have existed. This review briefly presents the pros and cons of the third generation vaccines, Moderna / NIAID and Pfizer - BioNTech, which are in phase 3 tests, based on lipid RNA nanoparticles. Great collaborative efforts are being invested so that soon the world population will receive doses of vaccines with proven efficacy and enable increased survival, since the pandemic has already caused many irreversible losses.
References
Campos, E. V. R., Pereira, A. E. S., De Oliveira, J. L., Carvalho, L. B., Guilger-Casagrande, M., De Lima, R., & Fraceto, L. F. (2020). How can nanotechnology help to combat COVID-19? Opportunities and urgent need. Journal of Nanobiotechnology, 18(1), 1–23. https://doi.org/10.1186/s12951-020-00685-4
Cucinotta, D., & Vanelli, M. (2020). WHO declares COVID-19 a pandemic. Acta Bio-Medica: Atenei Parmensis, 91(1), 157–160.
Huang, L., Rong, Y., Pan, Q., Yi, K., Tang, X., Zhang, Q., Wang, W., Wu, J., & Wang, F. (2020). SARS-CoV-2 vaccine research and development: conventional vaccines and biomimetic nanotechnology strategies. Asian Journal of Pharmaceutical Sciences.
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., & others. (2020). An mRNA Vaccine against SARS-CoV-2—Preliminary Report. New England Journal of Medicine.
Kim, Y. C., Dema, B., & Reyes-Sandoval, A. (2020). COVID-19 vaccines: breaking record times to first-in-human trials. Npj Vaccines, 5(1), 1–3.
Mahase, E. (2020a). Covid-19: UK approves Pfizer and BioNTech vaccine with rollout due to start next week. British Medical Journal Publishing Group.
Mahase, E. (2020b). Covid-19: What do we know about the late stage vaccine candidates? British Medical Journal Publishing Group.
Mulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Raabe, V., Bailey, R., Swanson, K. A., Li, P., Koury, K., Kalina, W., Cooper, D., Fontes-Garfias, C., Shi, P. Y., Türeci, Ö., Tompkins, K. R., Walsh, E. E., … Jansen, K. U. (2020). Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. https://doi.org/10.1038/s41586-020-2639-4
Pacheco, T. J. A., da Silva, F. de M., DE SOUZA, D. G., da Silva, V. C. M., & Faria, R. S. (2020). Coronavirus disease 2019 (COVID-19): Updated evidence of comparative overview, diagnosis and treatments. Revista Cereus, 12(3), 228–243.
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V, Cooper, D., Frenck, R. W., Hammitt, L. L., … Gruber, W. C. (n.d.). Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New England Journal of Medicine, 0(0), null. https://doi.org/10.1056/NEJMoa2034577
Sahin, U., Karikó, K., & Türeci, Ö. (2014). mRNA-based therapeutics—developing a new class of drugs. Nature Reviews Drug Discovery, 13(10), 759–780.
Shi, J., Votruba, A. R., Farokhzad, O. C., & Langer, R. (2010). Nanotechnology in drug delivery and tissue engineering: from discovery to applications. Nano Letters, 10(9), 3223–3230.
Walsh, E. E., Frenck Jr, R. W., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S.,
Neuzil, K., Mulligan, M. J., Bailey, R., & others. (2020). Safety and immunogenicity of two RNA-based COVID-19 vaccine candidates. New England Journal of Medicine.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Thyago José Arruda Pacheco; Victor Carlos Mello da Silva; Danielle Galdino de Souza
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
